Skip to content

DANCE

Atrial Fibrillation | Cardiac Surgery | Anticoagulant | Rivaroxaban | Apixaban | Dabigatran | Open Heart Surgery | Warfarin

Approximately 36,000 Canadians and 400,000 Americans undergo heart surgery every year. Many of these individuals will be on blood thinners after surgery to prevent strokes from due to pre-existing atrial fibrillation (AF) or a newly diagnosed AF.

The purpose of this study is to establish whether direct oral anticoagulants (DOACs) (ex: Rivaroxaban, Apixaban, etc.) are as safe as vitamin K antagonists (VKAs) (ex: Warfarin) in the first 90 days after heart surgery. The results of this study will impact the treatment of hundreds of thousands of patients in the world every year.

null

Participation Requirements

  • Sex:

    Any

  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria:
1. Age ≥18 years at the time of enrolment,
2. Open heart surgery in the last 10 days (or upcoming open heart surgery),
3. Atrial fibrillation requiring anticoagulation (including pre-existing or post-operative atrial fibrillation)
4. Written informed consent from either the patient or a substitute decision-maker.
Exclusion Criteria:
1. Mechanical valve replacement,
2. Antiphospholipid syndrome (triple positive),
3. Severe renal failure (Cockcroft-Gault equation; creatinine clearance <30 ml/min),
4. Known significant liver disease (Child-Pugh classification B and C),
5. Ongoing bleeding, hemorrhagic disorders, or bleeding diathesis,
6. Known contraindication for any direct oral anticoagulant or vitamin K antagonist,
7. Women who are pregnant, breastfeeding, or of childbearing potential,
8. Left ventricular thrombus,surgery including left ventricular assist device or cardiac transplant
10. Previously enrolled in this trial,
11. Follow-up not possible.
12. History of moderate or severe mitral valve lesion that is not corrected during cardiac surgery.

Study Location

University of Alberta
University of Alberta
Edmonton, Alberta
Canada

Contact Study Team

Primary Contact

Tracy Jordan

[email protected]
(780)407-1470
Primary Contact

Nasim Boroumand

[email protected]
780-407-2667
Primary Contact

Dr. Steven Meyer

null
780-407-1959
Study Sponsored By
University of Alberta
Participants Required
More Information
Study ID: Pro00113728